E Fund Management Co. Ltd. Trims Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

E Fund Management Co. Ltd. cut its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 37.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,165 shares of the company’s stock after selling 14,562 shares during the period. E Fund Management Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $181,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the first quarter worth $26,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares in the last quarter. Midwest Financial Group LLC purchased a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $90,000. Gilman Hill Asset Management LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter worth about $101,000. Finally, International Assets Investment Management LLC bought a new position in Recursion Pharmaceuticals in the 2nd quarter worth about $101,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RXRX has been the subject of a number of research reports. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. KeyCorp cut their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $9.40.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total transaction of $108,860.97. Following the completion of the sale, the director now owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $7.48, for a total transaction of $374,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at approximately $5,675,360.24. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the sale, the director now owns 7,177,116 shares in the company, valued at $68,254,373.16. The disclosure for this sale can be found here. Insiders sold a total of 243,129 shares of company stock worth $1,742,165 over the last three months. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Trading Up 0.4 %

Shares of NASDAQ RXRX opened at $6.94 on Friday. The business has a fifty day moving average price of $7.20 and a 200 day moving average price of $8.42. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.97 and a 1-year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The stock has a market capitalization of $1.95 billion, a P/E ratio of -4.34 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm’s quarterly revenue was up 30.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.38) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.